Sahlgrenska University Hospital-Vaestra Goetalandsregionen
Sahlgrenska University Hospital-Vaestra Goetalandsregionen is recorded as a service provider in 8 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 8 of 8 trials · Latest update first
A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive multiple sclerosis (PERSEUS)
Sponsor Genzyme Corp.
- Start (EU)
- Latest update
- Estimated end
International cooperative prospective study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the efficacy of Vinblastine
Sponsor GPOH gGmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
International Euro Ewing (iEuroEwing) trial for treatment optimisation in patients with Ewing sarcoma
Sponsor GPOH gGmbH
- Start (EU)
- Latest update
- Estimated end
Durvalumab after concurrent platinum/etoposide chemotherapy and high-dose twice-daily thoracic radiotherapy in limited stage small cell lung cancer – an open label, randomized phase III trial (DAHRTS)
Sponsor Norges Teknisk-Naturvitenskapelige Universitet NTNU
- Start (EU)
- Not reported
- Latest update
- Estimated end
I5T-MC-AACO: Global Study to Investigate Safety and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
Glo-BNHL: A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
Sponsor The University Of Birmingham
- Start (EU)
- Latest update
- Estimated end
A Phase 2b, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Safety and Efficacy of AD04 in Patients with Early Alzheimer’s Disease - ADVANCE
Sponsor Advantage Therapeutics GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
A randomized phase II study comparing atezolizumab after concurrent chemoradiotherapy with chemoradiotherapy alone in limited disease small-cell lung cancer
Sponsor Norwegian University Of Science And Technolology
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Sahlgrenska University Hospital-Vaestra Goetalandsregionen?
The 2026-10-09 snapshot links Sahlgrenska University Hospital-Vaestra Goetalandsregionen to 8 distinct CTIS trials. Recorded services include Clinical monitoring, Data management, Laboratory services, National Coordinating Center Sweden, among 10 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Sahlgrenska University Hospital-Vaestra Goetalandsregionen?
The most frequently recorded therapeutic areas are Haematological Malignancies, Immunology, Neurology, Solid Tumor Oncology. Recorded phases include Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Sahlgrenska University Hospital-Vaestra Goetalandsregionen conducted?
The linked trials record locations in 21 countries, including Sweden, Austria, Netherlands, Belgium, Germany. These are trial locations, not confirmed office locations or countries where Sahlgrenska University Hospital-Vaestra Goetalandsregionen delivered services.
What can this page tell me about Sahlgrenska University Hospital-Vaestra Goetalandsregionen's trial experience?
Browse 8 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Sahlgrenska University Hospital-Vaestra Goetalandsregionen. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Sahlgrenska University Hospital-Vaestra Goetalandsregionen